Volver

Elija su región

Corporate

Europa:

Flaga Albania Albania Flaga Alemania Alemania Flaga Bosnia y Herzegovina Bosnia y Herzegovina Flaga Bulgaria Bulgaria Flaga Croacia Croacia Flaga Cyprus Cyprus Flaga Dinamarca Dinamarca Flaga Eslovaquia Eslovaquia Flaga Eslovenia Eslovenia Flaga España España Flaga Estonia Estonia Flaga Gran bretaña Gran bretaña Flaga Hungría Hungría Flaga Italia Italia Flaga Kosovo Kosovo Flaga Letonia Letonia Flaga Lituania Lituania Flaga Luxemburgo Luxemburgo Flaga Macedonia Macedonia Flaga Montenegro Montenegro Flaga Polonia Polonia Flaga Portugal Portugal Flaga República Checa República Checa Flaga Rumania Rumania Flaga Serbia Serbia Flaga Suecia Suecia Flaga Suiza Suiza Flaga Turquía Turquía

Asia:

Flaga Hong Kong Hong Kong Flaga Kuwait Kuwait Flaga Liban Liban Flaga UAE UAE

Africa:

Flaga RPA RPA
Contacto

¡Contáctanos hoy mismo!

¿Quieres saber más sobre nuestros servicios? Completa el formulario a continuación y nos pondremos en contacto contigo lo antes posible para proporcionarte toda la información necesaria y responder a tus preguntas.

    Le informamos que estos datos serán incorporados al sistema de tratamiento titularidad de SEVIBE CELLS S.L. con CIF B64646912 y domicilio social sito en Av. Parc Tecnològic nº3, 08290, Cerdanyola del Vallès, con la finalidad de atender sus consultas y remitirle información relacionada que pueda ser de su interés.

    Imagen

    Información del Grupo FamiCord
    Última actualización: 06.2026

    Más información en: https://famicord.eu/

    Esta información pertenece al Grupo Famicord (no a Sevibe directamente). Hace referencia a:

    • Uso de progenitores hematopoyéticos de diferentes fuentes:
      • Adipose Tissue = tejido adiposo
      • Apheresis = aféresis
      • Bone Marrow = médula ósea
      • Bone Marrow (Apheresismily donor) = médula ósea (donante por aféresis)
      • Bone Marrow Family = médula ósea familiar
      • Cord Blood = sangre de cordón
      • Cord Tissue = tejido de cordón
      • Placenta blood = sangre de placente
    • A diferentes vías de aplicaciones:
      • Clinical Trial = ensayo clínico
      • Clinical Trial ALSTEM = ensayo clínico ALSTEM
      • Clinical Trial BIOOPA = ensayo clínico BIOOPA
      • Experimental Therapy = terapia experimental
      • Standard Therapy = terapia estándard

    Así mismo, desde los desplegables de la tabla se puede consultar la información sobre el tipo de trasplante, el diagnóstico, el área médica, el año, el país y la edad del receptor.

    Listado del Grupo Famicord

    Imagen
    Lp. Fuente Tipo de trasplante Diagnóstico Área médica Año Terapia País Edad del receptor
    201 Apheresis Allogeneic Chronic Myelomonocytic Leukemia (CMML) Hematology 2026 Standard Therapy Germany 56
    202 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 37
    203 Apheresis Allogeneic Sickle Cell Anemia Hematology 2026 Standard Therapy Germany 10
    204 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 71
    205 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
    206 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 51
    207 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
    208 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
    209 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Sweden 68
    210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 67
    211 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
    212 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Australia 57
    213 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
    214 Apheresis Allogeneic B-Cell Acute Lymphoblastic Leukemia (B-ALL) Hematology 2026 Standard Therapy Poland 46
    215 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
    216 Apheresis Allogeneic Primary Myelofibrosis (PMF) Hematology 2026 Standard Therapy Poland 59
    217 Apheresis Autologous T-cell Lymphoblastic Lymphoma Hematology 2026 Standard Therapy Germany 40
    218 Apheresis Autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    219 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 51
    220 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
    221 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 58
    222 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
    223 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    224 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    225 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
    226 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy United Kingdom 55
    227 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 65
    228 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Austria 43
    229 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 60
    230 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 58
    231 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Spain 66
    232 Apheresis Allogeneic Myelodysplastic Syndrome IB2 Hematology 2026 Standard Therapy Germany 59
    233 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 63
    234 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Israel 74
    235 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
    236 Apheresis Allogeneic Serum Amyloid A (SAA) Hematology 2026 Standard Therapy United Kingdom 11
    237 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 54
    238 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 52
    239 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 45
    240 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 62
    241 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 47
    242 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
    243 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 63
    244 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
    245 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 72
    246 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 30
    247 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    248 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 70
    249 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ireland 73
    250 Apheresis Allogeneic Other Leukemia, Specify, Chronic Neutrophilic Leukemia Hematology 2026 Standard Therapy USA 56
    251 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 60
    252 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 64
    253 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 66
    254 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
    255 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 69
    256 Apheresis Allogeneic CML Blast Crisis Hematology 2026 Standard Therapy Poland 38
    257 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 34
    258 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Bulgaria 49
    259 Apheresis Allogeneic Hodgkin lymphoma Hematology 2026 Standard Therapy Russian Federation 37
    260 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
    261 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 24
    262 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
    263 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    264 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Poland 63
    265 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 64
    266 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Argentine 52
    267 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 71
    268 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 55
    269 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
    270 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
    271 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 12
    272 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 71
    273 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 66
    274 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 63
    275 Apheresis Allogeneic T -Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 45
    276 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Croatia 57
    277 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
    278 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Kazachstan 8
    279 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
    280 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
    281 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 68
    282 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 65
    283 Apheresis Allogeneic Diffuse Large B-Cell Lymphoma Hematology 2026 Standard Therapy Germany 63
    284 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 66
    285 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 44
    286 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 57
    287 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy UK 62
    288 Apheresis Allogeneic Aplastic Anemia Hematology 2026 Standard Therapy Poland 22
    289 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
    290 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 68
    291 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Belgium 63
    292 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 47
    293 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 51
    294 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 70
    295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 28
    296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    297 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 73
    298 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
    299 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 10
    300 Apheresis Allogeneic T-cell non-Hodgkin lymphoma / NK Hematology 2026 Standard Therapy Poland 19